Elicera Therapeutics AB (OSTO:ELIC) Cash And Cash Equivalents : kr40.71 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Cash And Cash Equivalents?

Elicera Therapeutics AB's quarterly cash and cash equivalents increased from Sep. 2023 (kr25.88 Mil) to Dec. 2023 (kr29.38 Mil) and increased from Dec. 2023 (kr29.38 Mil) to Mar. 2024 (kr40.71 Mil).

Elicera Therapeutics AB's annual cash and cash equivalents declined from Dec. 2021 (kr52.39 Mil) to Dec. 2022 (kr43.82 Mil) and declined from Dec. 2022 (kr43.82 Mil) to Dec. 2023 (kr29.38 Mil).

Elicera Therapeutics AB Cash And Cash Equivalents Historical Data

The historical data trend for Elicera Therapeutics AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB Cash And Cash Equivalents Chart

Elicera Therapeutics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

0.03

11.57

52.39

43.82

29.38

Elicera Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial													41.79	40.12	25.88	29.38	40.71

Elicera Therapeutics AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Elicera Therapeutics AB (OSTO:ELIC) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Elicera Therapeutics AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB (OSTO:ELIC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

8E8:Germany

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines